SCHEMBL880087

SCHEMBL880087

Cc1ccccc1CNS(=O)(=O)N1CCOC1=O

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.48
KMT2A Q03164 3/20 0.45
MEN1 O00255 2/20 0.45
SMN1; SMN2 Q16637 1/20 0.42
CYP2A13 Q16696 1/20 0.41
GAA P10253 1/20 0.41
MAPT P10636 1/20 0.40
ALDH1A1 P00352 3/20 0.40
TSHR P16473 1/20 0.39
HTT P42858 1/20 0.39
P2RX7 Q99572 1/20 0.39
KDM4E B2RXH2 1/20 0.37
PTGS1 P23219 1/20 0.37
PTGS2 P35354 1/20 0.37
PIK3CD O00329 1/20 0.36
PIK3CA P42336 1/20 0.36
PIK3CB P42338 1/20 0.36
PIK3CG P48736 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL880082 0.87 HPGD (0.39) HPGDKMT2AMEN1SMN1; SMN2CYP2A13
SCHEMBL4909752 0.81 CA2 (0.46) HPGDSMN1; SMN2ALDH1A1KDM4E
SCHEMBL14861251 0.75 ALDH1A1 (0.59) HPGDKMT2AMEN1SMN1; SMN2GAA
SCHEMBL13183037 0.73 PKM (0.46) HPGDKMT2ATSHR
SCHEMBL17258596 0.72 ALDH1A1 (0.36) HPGDGAAMAPTALDH1A1HTT
SCHEMBL18007741 0.71 KDM4E (0.44) KMT2AMEN1ALDH1A1TSHRKDM4E
SCHEMBL3142704 0.71 ALDH1A1 (0.40) KMT2AALDH1A1TSHRHTT
SCHEMBL14907719 0.70 NUDT1 (0.40) PIK3CA
SCHEMBL23009276 0.70 PIK3CD (0.33) KDM4EPIK3CD
SCHEMBL13908429 0.69 MRGPRX4 (0.45) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9487517-B2 Spiroimidazolone derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-11-08 US disclosed
US-9169254-B2 Spiroimidazolone derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2015-10-27 US disclosed
US-9169254-B2 Spiroimidazolone derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2015-10-27 US disclosed
US-20120270838-A1 SPIROIMIDAZOLONE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2012-10-25 US disclosed
EP-2433940-A1 SPIROIMIDAZOLONE DERIVATIVE Chugai Seiyaku Kabushiki Kaisha (JP) 2012-03-28 EP disclosed
WO-2010126030-A1 SPIROIMIDAZOLONE DERIVATIVE 中外製薬株式会社 (JP) 2010-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120270838-A1 SPIROIMIDAZOLONE DERIVATIVE WNK3, REN, SGK3 HPGD 2068/4885KMT2A 3163/4885MEN1 276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.